Central to the challenge of treatment resistance in acute myeloid leukemia (AML) is the enigmatic role of the protein ALKBH1, as meticulously detailed by Dr. Jianjun Chen and his team. AML cells exploit a phenomenon known as codon-biased translation, enabling the preferential production of tumor-supportive proteins. ALKBH1 emerges as a key orchestrator in this process by remodeling the architecture of mitochondria, the cell’s energy hubs. This remodeling optimizes mitochondrial efficiency, supplying leukemia cells with an energetic advantage that bolsters survival and adaptation against targeted therapies like venetoclax. Experimental inhibition of ALKBH1, especially in concert with venetoclax treatment, yielded significant anti-leukemic effects with minimal toxicity in preclinical models, highlighting a promising therapeutic axis that could overcome refractory AML and perhaps other ALKBH1-driven malignancies.

Turning to breast cancer, researchers led by Dr. John Carpten have delivered an unprecedented genomic landscape analysis of triple-negative breast cancer (TNBC) in Black women. This aggressive subtype, characterized by the absence of estrogen, progesterone, and HER2 receptors, disproportionately affects younger African American women with poorer prognosis. By sequencing tumor genomes from over four hundred Black women, the study disclosed distinctive mutational patterns, notably a higher frequency of TP53 mutations and a lower prevalence of PIK3CA mutations compared to other populations. Notably, the tumors segregated into two distinct genomic subtypes with divergent clinical trajectories—one associated with younger age and better survival marked by a robust mutational burden, and another linked to older age, elevated body mass index, attenuated immune responses, and poorer outcomes. These findings not only provide crucial insights into the molecular underpinnings of racial disparities in TNBC but also point towards tailored immunotherapeutic and targeted intervention strategies that could enhance survival in this underserved demographic.

Immunotherapy innovation took a leap forward with research into Th9 cells, a subset of helper T cells endowed with formidable anti-tumor activity. The City of Hope team, including Drs. Michael Caligiuri and Shoubao Ma, dissected the molecular brakes imposed by YTHDF2, an RNA-binding protein that regulates the development and function of Th9 cells. By genetically removing YTHDF2, they unleashed a proliferation of hyperactive Th9 cells exhibiting enhanced tumor-killing capabilities. This revelation opens new avenues for CAR T cell engineering, where reprogrammed Th9 cells can be harnessed to confront solid tumors—long considered impregnable by traditional CAR T therapies. Such enhancements could dramatically expand the reach and potency of cellular immunotherapeutics.

In a striking and unconventional pivot, City of Hope scientists have developed a CAR T cell therapy for glioblastoma that incorporates chlorotoxin, a peptide derived from scorpion venom, to target malignant brain tumors with precision. This innovative approach, pioneered by neurosurgeon Dr. Behnam Badie and colleagues, exploits chlorotoxin’s natural affinity for glioblastoma cell membranes without harming normal brain tissue. Early-phase clinical trials demonstrated safety and tolerability, with CAR T cells persisting in the tumor microenvironment and achieving temporary disease stabilization in most patients despite the aggressive nature of glioblastoma. This pioneering work embodies a fusion of natural toxin biology and synthetic immunotherapy, offering renewed hope against one of the deadliest cancers known.

Further advancing the fight against recalcitrant tumors, City of Hope researchers engineered an oncolytic virus named CF33-hNIS-antiPDL1 designed to infiltrate and dismantle the immunosuppressive microenvironment of pancreatic ductal adenocarcinoma (PDAC). This virus not only selectively infects and lyses pancreatic cancer cells but also expresses a checkpoint inhibitor targeting PD-L1, a protein that tumors exploit to evade immune detection. In preclinical models, this dual-action viral therapy significantly curtailed tumor growth, enhanced immune cell infiltration, and prolonged survival. Notably, intraperitoneal administration of CF33-hNIS-antiPDL1 yielded superior efficacy over systemic delivery, highlighting the importance of delivery routes in virotherapy. These findings propel CF33 derivatives as potent candidates in the quest to breach pancreatic cancer’s formidable immune defenses.

Together, these advances epitomize the sophisticated convergence of molecular biology, genomic medicine, immunoengineering, and virotherapy in contemporary oncology research. City of Hope’s integrated model—from deep mechanistic studies, through translational preclinical evaluation, to pioneering clinical trials—embodies a paradigm shift towards personalized, multi-dimensional cancer care. The elucidation of ALKBH1’s mitochondrial modulation in AML enriches the therapeutic arsenal against drug resistance, while the human genomic insights into TNBC highlight the critical need to address racial disparities with precision medicine. CAR T cell evolutionary leaps through Th9 enhancement and venom-based targeting redefine immunotherapy’s potential against formidable solid tumors. Lastly, the marriage of viral engineering and checkpoint blockade holds promise to transform the grim landscape of pancreatic cancer prognosis.

These breakthroughs, supported by national and international collaborations, including licensing partnerships with biotechnology firms, reaffirm City of Hope’s status as a beacon of innovation in cancer research. Ensuring equitable access to these therapies and continued inclusion of diverse populations in clinical studies remain imperative. As these novel strategies progress from bench to bedside, they embody a collective promise to redefine cancer survivorship and ultimately translate scientific insight into lasting hope for patients worldwide.

Subject of Research: Acute Myeloid Leukemia, Triple-negative Breast Cancer, CAR T Cell Therapy, Glioblastoma, Pancreatic Cancer

Article Title: City of Hope Unveils Molecular and Therapeutic Innovations to Combat Resistant Cancers

News Publication Date: Not specified

Web References:
– https://www.cityofhope.org/
– https://aacrjournals.org/cancerdiscovery/article/10.1158/2159-8290.CD-24-1043/763931/ALKBH1-drives-tumorigenesis-and-drug-resistance
– https://www.nature.com/articles/s41588-025-02322-y
– https://www.nature.com/articles/s41590-025-02235-2
– https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00375-1
– https://www.sciencedirect.com/science/article/pii/S075333222500602X

References:
– Chen, J. et al. ALKBH1 Drives Tumorigenesis and Drug Resistance in AML. Cancer Discovery.
– Carpten, J. et al. Genomic Landscape and Distinct Subtypes of Triple-Negative Breast Cancer in Black Women. Nature Genetics.
– Caligiuri, M., Ma, S. YTHDF2 Regulates Th9 Cell Development and Enhances CAR T Immunotherapy. Nature Immunology.
– Badie, B., Barish, M., Brown, C. CLTX-CAR T Cells for Glioblastoma: Early Clinical Trial Outcomes. Cell Reports Medicine.
– Woo, Y. et al. CF33 Oncolytic Virus Engineered to Block PD-L1 in Pancreatic Cancer. Biomedicine & Pharmacotherapy.

Image Credits: City of Hope

Keywords: Myeloid leukemia, Triple-negative breast cancer, CAR T therapy, Glioblastoma, Pancreatic cancer, ALKBH1, TP53 mutation, YTHDF2, Chlorotoxin, Oncolytic virus, Immune checkpoint blockade, Cancer drug resistance

Conventional CAR T cell therapy requires a multi-step ex vivo process involving the isolation of a patient’s T cells, their activation, genetic modification, expansion, and rigorous quality control assays. This workflow commonly extends over two to three weeks, during which time delicate cellular manipulations can compromise T cell functionality, and rapid disease progression may outpace treatment availability. Furthermore, the personalized nature of such therapies restricts scalability, confining benefits to select patients within specialized centers.

The cutting edge concept of in vivo CAR T cell production foregoes extracorporeal cell processing by delivering CAR genetic constructs directly into T cells within the patient’s body. This approach utilizes finely engineered viral vectors, such as lentiviruses and adeno-associated viruses (AAVs), alongside emerging nonviral delivery systems, including lipid nanoparticles. Upon administration, these vectors specifically transduce T cells in situ, effectuating genetic reprogramming that endows them with tumor-targeting capabilities. This innovation has the potential to drastically reduce production complexities, cut timelines, and improve therapeutic potency by preserving T cell phenotypes in their native milieu.

One of the foremost advantages of in vivo CAR T therapy lies in its inherent scalability and potential to yield “off-the-shelf” CAR T cell products. Contrasting with the “one patient, one batch” model of ex vivo manufacturing, in vivo strategies could harness a more universal delivery modality, enabling broader patient reach and cost efficiencies unimaginable with current standards. Moreover, retaining T cells within their physiological environment mitigates the risk of functional exhaustion seen in cultured cells, thus enhancing efficacy and durability of tumor eradication.

Nanoparticle-based delivery systems exemplify a promising nonviral vector class facilitating efficient CAR gene transfection with minimal immunogenicity. Their ability to encapsulate nucleic acids and traverse biological barriers allows for targeted T cell modification without integrating viral components, thereby alleviating concerns regarding insertional mutagenesis. Advances in materials science have led to the design of nanoparticles optimized for stability, biodistribution, and cell-specific uptake, which are critical parameters for clinical translation.

Viral vectors such as lentiviruses and AAVs remain pivotal due to their high transduction efficiency and ability to confer stable CAR expression. Lentiviral vectors integrate into the T cell genome, ensuring persistent CAR expression, whereas AAVs tend to remain episomal, offering a safer but transient modification profile. The refinement of vector tropism and promoter elements continues to improve transgene expression specificity and intensity, enhancing the precision of in vivo CAR T cell engineering.

Despite the promise, the transition to in vivo CAR T cell production is not without formidable challenges. Precise targeting is essential to avoid off-target modification of non-T cell populations, which could provoke adverse effects or diminish therapeutic efficacy. Immunogenic responses to vector components or newly expressed CAR proteins pose risks of rapid clearance, reduced transgene expression, or systemic inflammation. Additionally, insertional mutagenesis induced by integrating vectors remains a safety concern necessitating rigorous preclinical assessment.

The rapidly progressing biology of certain malignancies makes the expedited timeline of in vivo CAR T cell generation especially compelling. Bypassing ex vivo expansion could dramatically shorten the interval between diagnosis and treatment administration, potentially altering disease trajectories. Furthermore, overcoming manufacturing bottlenecks could democratize access to CAR T therapy beyond specialized centers, fostering more equitable cancer care.

An important consideration in advancing in vivo CAR T therapies is balancing transfection efficiency with cost-effectiveness and safety profiles. While viral vectors offer superior gene transfer efficiencies, their production costs and biosafety infrastructure requirements can be prohibitive. Conversely, nonviral systems promise more affordable manufacturing and flexibility but often suffer from lower transduction rates. Intensive research aims to optimize these platforms, perhaps combining the strengths of both approaches to achieve the ideal therapeutic index.

Ongoing studies are exploring the integration of synthetic biology and genome editing tools to refine the specificity and functionality of in vivo-generated CAR T cells. Innovations such as inducible CAR expression systems and multispecific CAR constructs may be harnessed to enhance tumor targeting while minimizing off-tumor toxicity. Additionally, multiplexed delivery systems could facilitate simultaneous modification of multiple immune cell types, broadening the scope of adoptive immunotherapy.

In summary, in vivo CAR T cell therapy stands at the frontier of personalized medicine, poised to overcome the scalability and logistical obstacles of traditional CAR T manufacturing. Its capacity for rapid, efficient, and cost-effective generation of functional CAR T cells could revolutionize clinical oncology, especially for aggressive cancers needing urgent intervention. While challenges surrounding safety, targeting specificity, and delivery vector optimization remain, the trajectory of current research augurs well for the translation of this approach into routine clinical practice.

The evolution of CAR T cell engineering from complex ex vivo bioprocesses to streamlined in vivo genetic modification mirrors the broader trend in gene therapy toward minimally invasive, patient-centric interventions. As the field progresses, collaborative efforts among immunologists, bioengineers, and clinicians will be paramount to harnessing the full potential of in vivo CAR T cell production, ultimately transforming the landscape of cancer treatment and patient outcomes.

Subject of Research: In vivo production of CAR T cells and its therapeutic potential in cancer treatment.

Article Title: In vivo production of CAR T cell: Opportunities and challenges.

News Publication Date: 1-Nov-2025.

References: Zhiqiang Song, Yi Zhou, Binbin Wang, Yuke Geng, Gusheng Tang, Yang Wang, Jianmin Yang, In vivo production of CAR T cell: Opportunities and challenges, Genes & Diseases, Volume 12, Issue 6, 2025, 101612, DOI: 10.1016/j.gendis.2025.101612.

Image Credits: Genes & Diseases.

Keywords: Cancer genetics, CAR T cell therapy, in vivo CAR T production, gene therapy, viral vectors, nanoparticle delivery, hematological malignancies, immunotherapy.

The AAAS is renowned for its status as the oldest and largest general science organization, emphasizing the honor associated with being selected as a fellow. Such recognition is reserved for individuals who demonstrate exceptional achievements in various scientific domains, and Dr. Dou’s work on mixed-lineage leukemia proteins underscores her prominence in the field. MLL, the acronym for mixed-lineage leukemia, refers to a family of pathogens that can significantly influence cancer progression, particularly in leukemia and other malignancies. Thus, Dou’s research is not merely academic; it has real-world implications for treatment strategies in oncology.

Her esteemed role as associate director for basic research at the USC Norris Comprehensive Cancer Center allows her to directly influence ongoing investigations into how epigenetic mechanisms operate and affect cell differentiation. This area of research is crucial to comprehend how genetic information is expressed, enabling various types of cells and tissues to form from a single genetic blueprint. Dr. Dou’s insights into the relationship between chromatin structure and gene activation have provided vital information that enhances our understanding of how deviations in these processes can lead to devastating diseases.

Research into epigenetics, particularly concerning MLL enzymes, offers new hope for understanding cancer biology. When Dr. Dou first began her research on these proteins, very little was known about their intricate structures and functions. Over time, through meticulous investigation, she has elucidated the mechanisms underpinning these enzymes, uncovering molecular insights that could lead to the development of novel therapies. Such breakthroughs demonstrate not only her intellectual rigor but also the innovative nature of her approach to scientific inquiry.

Dr. Dou’s investigative journey has revealed that MLL enzymes play a pivotal role not only in normal cellular development but also in disease states, particularly in cancers like leukemia, breast cancer, and liver cancer. Their frequent mutations are indicative of the critical nature of these enzymes in oncogenesis, the process by which normal cells transform into cancerous cells. Her research strategy hinges on examining how these enzymes interact with chromatin, facilitating gene expression and cellular differentiation. The ability to manipulate such interactions could pave the way for targeted therapeutic strategies that specifically address the malfunctioning pathways associated with cancer.

Integral to Dr. Dou’s success has been her collaborations with other scientists and researchers in diverse fields. This interdisciplinary approach has enabled her to expand the scope of her research beyond cancer, investigating the role of MLL enzymes in various biological systems, including the heart and brain. With each study, Dr. Dou illustrates how science thrives at the intersection of disciplines and disciplines, spurring new avenues of investigation that could yield transformative insights.

An essential aspect of scientific exploration is the identification of new questions that emerge from addressing existing inquiries. As Dr. Dou aptly notes, her drive stems from the thrill of discovering the unknown, where answering one question often leads to a cascade of new inquiries. In her view, this curiosity propels science forward, calling for continuous inquiry into the enigmas of biological processes and genome functioning, particularly in the field of epigenetics.

Dr. Dou’s work has significant implications for drug development as well. Through systematic study and exploration of MLL proteins, she has taken steps towards creating therapeutic agents designed to inhibit their enzymatic activity. Such advancements could ultimately lead to more effective treatment options for patients suffering from cancer. Additionally, understanding the functional dynamics of MLL enzymes is critical in creating precision medicine approaches tailored to individual patient profiles, marking a crucial step forward for oncology.

Recognizing the importance of her team, Dr. Dou highlights that her accomplishments are the result of collaborative efforts within her lab. As the driving force behind significant advancements in the understanding of MLL enzymes, she has fostered an environment that promotes shared learning and discovery. Researchers working alongside Dr. Dou are vital contributors, participating in the journey from fundamental research to the potential application of their findings in clinical settings.

Throughout her career, Dr. Dou has received numerous accolades for her innovative research, including prestigious awards from the Leukemia & Lymphoma Society and the American Association for Cancer Research. Her involvement in various scientific committees, such as serving as chair of the NIH’s Cancer Genetics Study Section, underscores the respect she commands within the scientific community. Her track record showcases an enduring commitment to advancing our understanding of cancer and the broader biological implications of genetic research.

As she reflects on her new designation as an AAAS fellow, Dr. Dou expresses a desire to use her platform to emphasize the importance of recognizing scientific contributions in society. In an era when scientific innovation is critical for addressing global health challenges, her work serves as a reminder that advancements in understanding cancer biology can translate into tangible benefits for patients. Dr. Dou’s career path highlights the interconnectedness of scientific endeavor, collaboration, and mentorship, showcasing how these elements converge to push the boundaries of knowledge.

Looking ahead, Dr. Dou aims to leverage advancements in big data and computational technology to propel her research further. As she pursues uncharted territory within molecular biology, her holistic perspective seeks not only to deepen our understanding of single processes but also to foster integrative knowledge that resonates across multiple biological domains. With such aspirations, her commitment to interdisciplinary collaboration holds the promise of not just understanding biology better but translating that understanding into effective treatment strategies for patients dealing with cancer and other diseases.

The evolution of Dr. Dou’s research and her recognition as a new AAAS fellow illustrates the ongoing journey of scientific discovery. With each finding and breakthrough, she not only contributes to a deeper understanding of molecular biology but also inspires future generations of scientists to continue exploring the complexities of life at a cellular level. Dr. Dou’s unyielding curiosity serves as a model for aspiring researchers and emphasizes the importance of contributing to the collective knowledge that ultimately benefits humanity.

In conclusion, Dr. Yali Dou’s election to the AAAS as a fellow epitomizes the profound impact of dedicated scientific inquiry. Her pioneering work in cancer research through the lens of epigenetics sets a remarkable precedent for the future of molecular biology. As she continues her investigations, the scientific community eagerly anticipates the new discoveries and advancements that will emerge from her laboratory, enriching our understanding of biology and improving therapeutic options for patients worldwide.

Subject of Research: Mixed-Lineage Leukemia Proteins and Epigenetics
Article Title: Dr. Yali Dou Elected AAAS Fellow for Pioneering Research in Cancer
News Publication Date: October 2023
Web References: USC Keck School of Medicine, USC Norris Comprehensive Cancer Center
References: N/A
Image Credits: Steve Cohn

Keywords: Cancer Research, Epigenetics, Molecular Biology, MLL Proteins, Drug Development, Scientific Collaboration, Biomedical Research, Precision Medicine, Leukemia, Scientific Awards, AAAS Fellow, Gene Expression.